BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Supplemental material This content has been supplied by the author(s). Provenance and peer review Not commissioned externally peer reviewed. PH: Study conception and design, analysis and interpretation of data, critical revision of manuscript, guarantor.įunding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. AT: Data acquisition, analysis, and interpretation of data. NC, JS, AdB, AG, RR, BA, GDA, EIB, FH, RP, MZM, TD, GP, ER, and FM: Analysis and interpretation of data, critical revision of manuscript. JPR: Analysis and interpretation of data, drafting and critical revision of manuscript. ER: Data collection, critical revision of manuscript. Twitter Aletti, HP: Study conception and design, data acquisition, analysis and interpretation of data, manuscript writing. Nineteen patients receiving adjuvant chemotherapy had lower estimated 5-year progression-free survival compared with patients not receiving chemotherapy (49.7% vs 91.1%, p<0.001 HR 9.15 (95% CI 3.62 to 23.1)). Five-year progression-free survival was worse for patients with advanced stages (FIGO stage IA/B vs IC: HR 5.09 (95% CI 1.53 to 16.9) FIGO stage IA/B vs II–IV: HR 5.62 (95% CI 1.58 to 19.9)). Five-year progression-free survival was 86.1% and estimated overall survival was 95.7%. After a median follow-up of 61 months (range 0–209), 10.7% of patients (n=18) had recurrent disease and 4.8% (n=8) died of disease. In addition, 36 (21.4%) patients underwent fertility-sparing surgery. 66.7% (n=112) of patients underwent surgical restaging, of whom 17.9% (n=20) were moved to a higher stage. With regard to stage distribution, 54.2% (n=91) of patients were FIGO stage IA, 1.2% (n=2) were stage IB, 26.8% (n=45) were stage IC, and 17.9% (n=30) were FIGO stage II–IV. Results A total of 168 patients with primary adult granulosa cell tumors were included.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |